GlassScriptPhysician profile
Thomas T Kizy
NPI 1457637506
$3,558.99
in general payments reported to CMS, 2019-2025
30 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $107 · 2021: $270 · 2022: $547 · 2023: $798 · 2024: $611 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $652.88 | 2019-2025 | Sublocade |
| Abbvie INC. | $648.30 | 2021-2025 | |
| Novo Nordisk INC | $333.20 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $269.04 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.63 | 2022-2025 | Caplyta |
| Exact Sciences Corporation | $156.23 | 2023-2025 | Cologuard Collection Kit |
| Orexo US, INC. | $155.22 | 2019-2025 | Zubsolv |
| Axsome Therapeutics, INC. | $147.11 | 2023-2025 | Auvelity, Sunosi |
| Amgen INC. | $140.88 | 2023-2025 | Repatha, Otezla, Repatha |
| Braeburn INC. | $124.59 | 2023-2025 | Brixadi |
| Pfizer INC. | $96.93 | 2019-2024 | |
| Alkermes, INC. | $80.49 | 2023-2024 | Vivitrol, Vivitrol |
| Glaxosmithkline, LLC. | $72.12 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $64.97 | 2025 | Rexulti |
| Antares Pharma, INC. | $57.32 | 2024 | Xyosted, Tlando |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $40.07 | 2023-2025 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $32.64 | 2023 | |
| Tolmar, INC. | $30.54 | 2024-2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.10 | 2021 | |
| Dexcom, INC. | $25.62 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $24.05 | 2022 | |
| Bioventus LLC | $20.84 | 2019 | |
| Almatica Pharma LLC | $20.26 | 2022 | |
| Biodelivery Sciences International, INC. | $17.19 | 2020 | |
| Lundbeck LLC | $16.70 | 2025 | Rexulti |
| Bardy Diagnostics, INC. | $14.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.06 | 2020 | |
| Allergan, INC. | $14.06 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.90 | 2023 | Belbuca |
| Merck Sharp & Dohme LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kizy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.